Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01744054
(Logistics regarding PET/CT portion of study)
The successful localization of the y90 microspheres by PET/MR and/or PET/CT scans would be a useful tool in individualizing patient care after the radioembolization procedure. The information from a PET/MR or PET/CT scan would allow for early evaluation of the technical success of the procedure.
Evaluate y90-PET/MRI and PET/CT for potential on reporting presence of extrahepatic deposition of microspheres [ Time Frame: 1 day (one time event for patient) ]
A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine any presence of extrahepatic deposition of microspheres.
Evaluate y90-PET/MRI and PET/CT for potential on reporting technical success of radioembolization [ Time Frame: 1 day (one time event for patient) ]
A diagnostic radiologist and a nuclear medicine physician will evaluate the images and will determine whether technical success of the procedure can be determined. They will rate the images if they are 'adequate' to report on these two measures.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Participant must successfully complete the MRI screening form if receiving an MRI
Participant must be scheduled to undergo radioembolization for any indication
Participant must be ≥ 18 years of age
Participant must be able to understand and willing to sign an Institutional Review Board (IRB)-approved written informed consent document
Participant must not have any contraindications to MRI scanning
Patient must not be pregnant or breastfeeding
If agreeing to MRI contrast, participant must not have renal insufficiency (glomerular filtration rate (GFR < 30 mL/min/1.73 m2) measured within the past 60 days
If agreeing to MRI contrast, participant must not be on dialysis
If agreeing to MRI contrast, participant must not have had a prior allergic reaction to gadolinium-based contrast agents
PET/MRI or PET/CT is not able to be scheduled within 72 hours of radioembolization